• Corpus ID: 80284656

Intravenous positive inotropic therapy for acute decompensated heart failure

@article{Kasikcioglu2006IntravenousPI,
  title={Intravenous positive inotropic therapy for acute decompensated heart failure},
  author={Hulya Akhan Kasikcioglu and Neşe Çam},
  journal={Archives of the Turkish Society of Cardiology},
  year={2006},
  volume={34},
  pages={316-322}
}
Kalp yetersizli¤i Avrupa ülkeleri genelinde tahmini s›kl›¤› %0.4-2 olan ve yafll› nüfusun artmas›yla bireysel ve toplumsal aç›dan giderek büyüyen bir sorundur. Dünya Sa¤l›k Örgütü istatistiklerine göre dünya çap›nda 22.6 milyon kiflide kalp yetersizli¤i oldu¤u varsay›lmaktad›r. Avrupa ülkelerinde 75 yafl›n alt›ndaki hastalarda kalp yetersizli¤inin en s›k nedeni koroner arter hastal›¤›na ba¤l› miyokard disfonksiyonudur. 
Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure
  • A. Taşal, M. Demir, E. Acarturk
  • Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2014
TLDR
This study showed that repeated LS treatment is more effective compared to the single dose LS treatment in improving clinical status, hemodynamic and laboratory parameters in patients with acute exacerbation of advanced heart failure.

References

SHOWING 1-10 OF 35 REFERENCES
Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure
TLDR
Levosimendan caused rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure and appeared to improve dyspnea and fatigue, accompanied by symptom improvement and were not associated with a significant increase in the number of adverse events.
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Inotropic therapy for heart failure.
Looking back reveals how the direction of therapy for heart failure has changed since the inception of the first large clinical trial of vesnarinone, an inotropic agent, in April 1990. At that time...
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
Effects of Levosimendan on Left Ventricular Functional Remodelling and Exercise Intolerance: A Tissue Doppler Study
TLDR
It is shown that the progress of ventricular function after levosimendan treatment in patients with exercise intolerance could be monitored effectively by Sm velocity measurements using TDI.
Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization.
TLDR
In trial populations dominated by mild-moderate heart failure, the majority of patients with left ventricular dysfunction have preserved cardiac output at rest and are limited primarily by impaired volume regulation and diminished cardiac output responses to exercise.
...
...